Clinical Updates and Perspectives in VMS Management

Fiona C. Baker, PhD, outlines the NIRVANA study’s design and goals, noting its focus on evaluating elinzanetant’s impact on vasomotor symptoms and sleep-related outcomes.

Fiona C. Baker, PhD, reviews NIRVANA’s findings showing early onset of relief for both VMS and sleep disturbances, supported by patient-reported improvements in sleep quality, duration, and nighttime awakenings.

Fiona C. Baker, PhD, emphasizes the importance of patient-reported outcomes in assessing elinzanetant’s overall benefit, including insights on symptom recurrence and quality-of-life improvements.

Fiona C. Baker, PhD, compares elinzanetant with current therapeutic options, noting how its profile aligns with the needs of patients experiencing both VMS and sleep disturbances.